In January 2023, US pharma major AbbVie revealed that it has agreed a back-loaded partnership and option accord with Immunome directed to the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome's Discovery Engine.The company’s initial focus is on discovering and developing therapeutics in oncology internally and in collaboration with partners.